RadNet, Inc. (RDNT) – What Are Brokerages Saying About This Stock?

RadNet, Inc. (NASDAQ:RDNT – Get Free Report) has received an average rating of “Moderate Buy” from the nine analysts that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $89.67.

Several equities research analysts have issued reports on the stock. KeyCorp raised their price target on shares of RadNet from $92.00 to $95.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 10th. Zacks Research lowered shares of RadNet from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 9th. Barclays upped their price objective on shares of RadNet from $65.00 to $79.00 and gave the company an “overweight” rating in a research note on Friday, August 28th. Raymond James Financial restated a “strong-buy” rating on shares of RadNet in a research report on Tuesday, September 22nd. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of RadNet in a research note on Friday, July 31st.

Get Our Latest Analysis on RDNT

RadNet Price Performance

Shares of NASDAQ:RDNT opened at $69.71 on Friday. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.49 and a current ratio of 1.49. The business’s fifty day moving average price is $72.71 and its two-hundred day moving average price is $65.56. The stock has a market cap of $5.49 billion, a PE ratio of -240.38 and a beta of 1.42. RadNet has a one year low of $50.82 and a one year high of $85.84.

RadNet (NASDAQ:RDNT – Get Free Report) last released its quarterly earnings results on Sunday, November 8th. The medical research company reported $0.30 earnings per share for the quarter, topping analysts’ consensus estimates of $0.22 by $0.08. The company had revenue of $638.26 million during the quarter, compared to analysts’ expectations of $639.97 million. RadNet had a positive return on equity of 3.14% and a negative net margin of 0.94%. The business’s revenue for the quarter was up 22.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.20 earnings per share. On average, analysts forecast that RadNet will post 0.56 EPS for the current fiscal year.

Insider Transactions at RadNet

In other news, EVP Mital Patel sold 44,661 shares of the stock in a transaction dated Wednesday, November 11th. The shares were sold at an average price of $78.51, for a total transaction of $3,506,335.11. Following the transaction, the executive vice president directly owned 155,514 shares in the company, valued at $12,209,404.14. This represents a 22.31% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 5.14% of the company’s stock.

Institutional Investors Weigh In On RadNet

Institutional investors have recently bought and sold shares of the stock. Hantz Financial Services Inc. raised its stake in RadNet by 18.8% during the third quarter. Hantz Financial Services Inc. now owns 872 shares of the medical research company’s stock worth $60,000 after purchasing an additional 138 shares during the period. SteelPeak Wealth LLC grew its stake in shares of RadNet by 0.6% during the 3rd quarter. SteelPeak Wealth LLC now owns 25,251 shares of the medical research company’s stock valued at $1,741,000 after buying an additional 151 shares during the period. Arizona State Retirement System grew its stake in shares of RadNet by 0.9% during the 2nd quarter. Arizona State Retirement System now owns 18,203 shares of the medical research company’s stock valued at $1,123,000 after buying an additional 160 shares during the period. Oppenheimer & Co. Inc. increased its holdings in shares of RadNet by 1.7% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 10,303 shares of the medical research company’s stock worth $710,000 after buying an additional 175 shares during the last quarter. Finally, PNC Financial Services Group Inc. increased its holdings in shares of RadNet by 2.9% during the 1st quarter. PNC Financial Services Group Inc. now owns 7,392 shares of the medical research company’s stock worth $413,000 after buying an additional 207 shares during the last quarter. 77.90% of the stock is currently owned by hedge funds and other institutional investors.

RadNet Company Profile

(Get Free Report)

RadNet, Inc. operates outpatient diagnostic imaging centers in the United States. Its centers provide services including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), mammography, ultrasound, X-ray and nuclear medicine imaging. The company serves patients, physicians and healthcare organizations, with operations across several states, including California, Delaware, Florida, Maryland, New Jersey and New York. Its imaging centers offer diagnostic services for a range of medical needs, from routine screening to specialized examinations.

Featured Stories

Analyst Recommendations for RadNet (NASDAQ:RDNT)

Receive News & Ratings for RadNet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet and related companies with MarketBeat.com's FREE daily email newsletter.